TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
复制标题
晚期胃肠道基质肿瘤中的TKI治疗测序。
DOI：
10.1007/s40265-022-01820-1
复制
发表时间：
2023-01
期刊：
影响因子：
11.5
通讯作者：
Heinrich, Michael C.
中科院分区：
文献类型：
--
作者：
Khosroyani, Homma M.;Klug, Lillian R.;Heinrich, Michael C.
在21世纪初之前，由于缺乏有效的治疗方法，晚期胃肠道间质瘤（GIST）患者的预后非常差。酪氨酸激酶抑制剂在世纪之交的发展显著提高了GIST患者的总生存率。伊马替尼在酪氨酸激酶抑制剂治疗GIST的首个临床试验中取得巨大成功，导致其被批准用于晚期GIST的一线治疗；本研究对所有患者开放，不局限于任何GIST亚型。导致二线、三线和四线治疗晚期GIST获批的试验也对所有晚期/转移性GIST患者开放。只有回顾起来，我们才认识到分子亚型在这些研究中观察到的结果中所起的作用。在这篇综述中，我们讨论了导致美国食品和药物管理局批准伊马替尼（一线）、舒尼替尼（二线）、瑞戈非尼（三线）和瑞普雷替尼（四线）用于晚期kit突变GIST的研究。此外，我们回顾了关于GIST分子亚型的信息如何被用于加速非kit突变GIST的其他靶向治疗的批准，导致另外五种用于治疗特定GIST分子亚型的药物获得批准。我们还讨论了我们对分子亚型的理解将如何在治疗晚期GIST的下一代治疗方法中发挥作用。
Prior to the early 2000s, patients with advanced gastrointestinal stromal tumors (GIST) had very poor prognoses owing to a lack of effective therapies. The development of tyrosine kinase inhibitors at the turn of the century significantly improved the overall survival for patients with GIST. The resounding success of imatinib in the first clinical trial of a tyrosine kinase inhibitor to treat GIST led to its approval for first-line therapy for advanced GIST; this study was open to all comers and not restricted to any GIST subtype(s). The trials that led to the approvals of second-, third-, and fourth-line therapy for advanced GIST were also open to all patients with advanced/metastatic GIST. Only in retrospect do we realize the role that the molecular subtypes played in the results observed in these studies. In this review, we discuss the studies that led to the US Food and Drug Administration approval of imatinib (first line), sunitinib (second line), regorafenib (third line), and ripretinib (fourth line) for advanced KIT-mutant GIST. In addition, we review how information about GIST molecular subtypes has been used to accelerate the approval of other targeted therapies for non-KIT mutant GIST, leading to the approval of five additional drugs indicated for the treatment of specific GIST molecular subtypes. We also discuss how our understanding of the molecular subtypes will play a role in the next generation of therapeutic approaches for treating advanced GIST.
登录
查看更多内容
影响因子：
17.1
作者：
Banks, Erica;Grondine, Michael;Anjum, Rana
通讯作者：
Anjum, Rana
影响因子：
45.3
作者：
Blanke, Charles D.;Rankin, Cathryn;Borden, Ernest C.
通讯作者：
Borden, Ernest C.
影响因子：
11.5
作者：
Cassier, Philippe A.;Fumagalli, Elena;Hohenberger, Peter
通讯作者：
Hohenberger, Peter
影响因子：
50.5
作者：
Ben-Ami, E.;Barysauskas, C. M.;George, S.
通讯作者：
George, S.
DOI：
10.1016/s1470-2045(20)30168-6
发表时间：
2020-07
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Blay JY;Serrano C;Heinrich MC;Zalcberg J;Bauer S;Gelderblom H;Schöffski P;Jones RL;Attia S;D'Amato G;Chi P;Reichardt P;Meade J;Shi K;Ruiz-Soto R;George S;von Mehren M
通讯作者：
von Mehren M